Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 3/Signature 2

EditHistoryDelete

Mark reviewed

Your review change was submitted

Needs review

Curated date: 2024/11/08

Curator: KateRasheed

Revision editor(s): KateRasheed

Source: Additional file 4: Figure S4

Description: Differentially abundant bacterial taxa between the naive and TB + HRZ groups at 2months into anti-tuberculosis HR(H-Isoniazid, R-Rifampin) therapy.

Abundance in Group 1: decreased abundance in TB +HRZ group - 2months into HR therapy(W12)

NCBI	Quality Control	Links
Acetivibrio
Sporobacter
Hespellia
Christensenella
Gordonibacter
Ethanoligenens
Robinsoniella
Anaerovorax
Alkaliphilus
Butyricicoccus
Stomatobaculum
Acidaminobacter
Dorea
Tyzzerella
Asaccharobacter
Caloramator
Arthrobacter
Syntrophococcus
Acetanaerobacterium
Ruminococcus
Pseudobutyrivibrio
unclassified Roseburia
Clostridium
Pediococcus
Odoribacter
Romboutsia
Peptococcus
Turicibacter
Dysgonomonas
Erysipelotrichaceae
Coprobacter
Bacteroides

Revision editor(s): KateRasheed